Dr. Michael Liss explores the critical role of the gut microbiome in cancer prevention, treatment, and overall patient wellness. Highlighting the intersection of genetics, lifestyle, and gut bacteria, he discusses how microbiome testing and personalized interventions—such as probiotics and dietary guidance—can support immunotherapy, reduce chemotherapy side effects, and optimize patient outcomes.
After being diagnosed with Stage IVa Head and Neck Squamous Cell Carcinoma (HNSCC), our founder experienced firsthand the physical and biological stress that cancer and its treatments place on the body. During treatment and recovery, careful attention was given to stabilizing key biological systems—supporting immune balance, micronutrient pathways, metabolic health, gut microbiome stability, and neurological signaling.
Over time, patterns began to emerge suggesting that maintaining stability within the body’s internal environment—the host—may play an important role in how patients tolerate treatment and recover.
Following remission, those observations became the starting point for a deeper effort: reverse-engineering the supportive strategies that appeared to help maintain biological resilience during treatment.
What began as a personal investigation evolved into the foundation of a larger system. By combining clinical observations, biological modeling, and structured data tracking, the concepts developed during that experience were translated into a Host Modulation platform and Medical Digital Twin (MDT) architecture designed to monitor and support host-state stability over time.
Blueprint to Beat Cancer was created to bring these insights into a structured, research-driven framework that could help support other patients navigating cancer treatment—while contributing data and insights that may help researchers better understand the role of the host environment in cancer care.






